Oncolytics Biotech (ONCY) Competitors $0.55 -0.02 (-3.64%) Closing price 04:00 PM EasternExtended Trading$0.56 +0.01 (+2.18%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. ELDN, CRDF, VYGR, ALMS, FULC, YMAB, BTMD, GNFT, INMB, and ESPRShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Eledon Pharmaceuticals (ELDN), Cardiff Oncology (CRDF), Voyager Therapeutics (VYGR), Alumis (ALMS), Fulcrum Therapeutics (FULC), Y-mAbs Therapeutics (YMAB), biote (BTMD), Genfit (GNFT), INmune Bio (INMB), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Eledon Pharmaceuticals Cardiff Oncology Voyager Therapeutics Alumis Fulcrum Therapeutics Y-mAbs Therapeutics biote Genfit INmune Bio Esperion Therapeutics Oncolytics Biotech (NASDAQ:ONCY) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership. Does the MarketBeat Community prefer ONCY or ELDN? Oncolytics Biotech received 132 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 73.68% of users gave Eledon Pharmaceuticals an outperform vote while only 68.67% of users gave Oncolytics Biotech an outperform vote. CompanyUnderperformOutperformOncolytics BiotechOutperform Votes16068.67% Underperform Votes7331.33% Eledon PharmaceuticalsOutperform Votes2873.68% Underperform Votes1026.32% Do insiders and institutionals have more ownership in ONCY or ELDN? 6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer ONCY or ELDN? Oncolytics Biotech presently has a consensus target price of $4.33, indicating a potential upside of 673.81%. Eledon Pharmaceuticals has a consensus target price of $12.50, indicating a potential upside of 270.37%. Given Oncolytics Biotech's higher probable upside, research analysts clearly believe Oncolytics Biotech is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, ONCY or ELDN? Oncolytics Biotech is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$20.56M-$0.30-1.87Eledon PharmaceuticalsN/AN/A-$116.54M-$2.36-1.43 Which has more volatility and risk, ONCY or ELDN? Oncolytics Biotech has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Is ONCY or ELDN more profitable? Oncolytics Biotech's return on equity of -141.15% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.15% -84.73% Eledon Pharmaceuticals N/A -189.99%-28.17% Does the media favor ONCY or ELDN? In the previous week, Eledon Pharmaceuticals had 6 more articles in the media than Oncolytics Biotech. MarketBeat recorded 7 mentions for Eledon Pharmaceuticals and 1 mentions for Oncolytics Biotech. Eledon Pharmaceuticals' average media sentiment score of 1.17 beat Oncolytics Biotech's score of 0.93 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Oncolytics Biotech Positive Eledon Pharmaceuticals Positive SummaryOncolytics Biotech and Eledon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.40M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.077.3222.5518.49Price / SalesN/A239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book2.076.436.694.25Net Income-$20.56M$143.21M$3.22B$248.31M7 Day Performance-3.99%1.24%1.11%1.12%1 Month Performance6.26%6.09%3.59%3.68%1 Year Performance-50.00%-3.34%15.65%5.19% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.5452 of 5 stars$0.55-3.6%$4.33+687.9%-48.6%$47.53MN/A-2.0430Upcoming EarningsELDNEledon Pharmaceuticals2.18 of 5 stars$3.28+1.2%$12.50+281.1%+32.2%$196.41MN/A-1.6310Upcoming EarningsShort Interest ↑News CoverageCRDFCardiff Oncology1.4615 of 5 stars$2.95+2.4%$11.67+295.5%-37.2%$196.25M$683,000.00-3.1420News CoverageVYGRVoyager Therapeutics4.5873 of 5 stars$3.53+1.7%$13.97+295.6%-54.5%$195.26M$80.00M4.97100ALMSAlumis2.5252 of 5 stars$4.12-3.7%$25.86+527.6%N/A$194.56MN/A0.00N/AAnalyst ForecastGap DownFULCFulcrum Therapeutics1.7844 of 5 stars$3.57+1.1%$8.63+141.6%-46.0%$192.71M$80M-11.52100Earnings ReportNews CoverageYMABY-mAbs Therapeutics3.8197 of 5 stars$4.23+3.2%$17.40+311.3%-72.1%$191.27M$87.69M-7.83150Upcoming EarningsShort Interest ↓News CoverageBTMDbiote3.7502 of 5 stars$3.47+1.2%$8.00+130.5%-39.6%$189.84M$197.19M13.35194Upcoming EarningsPositive NewsGNFTGenfit1.3638 of 5 stars$3.67+0.8%$13.00+254.2%+17.1%$183.49M$76.06M0.00120Short Interest ↑Gap DownINMBINmune Bio2.3449 of 5 stars$7.90+1.0%$22.80+188.6%-33.6%$181.57M$14,000.00-3.6210Upcoming EarningsNews CoveragePositive NewsESPREsperion Therapeutics3.4411 of 5 stars$0.91-1.4%$6.42+607.2%-49.3%$179.78M$332.31M-1.42200Upcoming EarningsAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Eledon Pharmaceuticals Competitors Cardiff Oncology Competitors Voyager Therapeutics Competitors Alumis Competitors Fulcrum Therapeutics Competitors Y-mAbs Therapeutics Competitors biote Competitors Genfit Competitors INmune Bio Competitors Esperion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONCY Stock Free ONCY Stock Alerts